Amneal Gross Profit Margin vs Asset Turnover Analysis

AMRX Stock

USD 8.58 0.32 3.87%

Amneal Pharmaceuticals, financial indicator trend analysis is way more than just evaluating Amneal Pharmaceuticals, prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Amneal Pharmaceuticals, is a good investment. Please check the relationship between Amneal Pharmaceuticals, Gross Profit Margin and its Asset Turnover accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amneal Pharmaceuticals, Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Gross Profit Margin vs Asset Turnover

Gross Profit Margin vs Asset Turnover Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Amneal Pharmaceuticals, Gross Profit Margin account and Asset Turnover. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Amneal Pharmaceuticals,'s Gross Profit Margin and Asset Turnover is 0.82. Overlapping area represents the amount of variation of Gross Profit Margin that can explain the historical movement of Asset Turnover in the same time period over historical financial statements of Amneal Pharmaceuticals, Class, assuming nothing else is changed. The correlation between historical values of Amneal Pharmaceuticals,'s Gross Profit Margin and Asset Turnover is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Gross Profit Margin of Amneal Pharmaceuticals, Class are associated (or correlated) with its Asset Turnover. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Asset Turnover has no effect on the direction of Gross Profit Margin i.e., Amneal Pharmaceuticals,'s Gross Profit Margin and Asset Turnover go up and down completely randomly.

Correlation Coefficient

0.82

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Gross Profit Margin

Asset Turnover

The ratio of net sales to average total assets, indicating how efficiently a company uses its assets to generate sales.

Most indicators from Amneal Pharmaceuticals,'s fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Amneal Pharmaceuticals, current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amneal Pharmaceuticals, Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

At this time, Amneal Pharmaceuticals,'s Enterprise Value Over EBITDA is fairly stable compared to the past year. Enterprise Value Multiple is likely to rise to 8.80 in 2025, whereas Selling General Administrative is likely to drop slightly above 281.2 M in 2025.

	2022	2023	2024	2025 (projected)
Gross Profit	784.7M	820.6M	943.6M	675.9M
Total Revenue	2.2B	2.4B	2.8B	1.7B

Gross Profit Total Revenue

Amneal Pharmaceuticals, fundamental ratios Correlations

	Total Assets	Common Stock Shares Outstanding	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Good Will	Short Term Investments	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Inventory	Other Current Assets	Other Stockholder Equity
Total Assets		0.49	0.51	0.87	0.84	0.78	-0.95	0.85	0.9	-0.35	0.66	0.67	0.96	0.83	0.55	0.92	0.66	0.85	0.93	-0.79	0.94	0.94	0.71	0.86	0.93	0.94
Common Stock Shares Outstanding	0.49		0.56	0.76	0.35	0.47	-0.63	0.7	0.7	-0.57	0.25	0.31	0.63	0.62	0.17	0.69	0.3	0.72	0.73	-0.63	0.7	0.68	0.76	0.76	0.63	0.65
Other Current Liab	0.51	0.56		0.73	0.13	0.21	-0.43	0.49	0.51	-0.53	-0.26	0.25	0.43	0.36	0.11	0.5	0.25	0.67	0.7	-0.35	0.54	0.52	0.77	0.72	0.53	0.54
Total Current Liabilities	0.87	0.76	0.73		0.56	0.67	-0.87	0.88	0.93	-0.66	0.39	0.45	0.87	0.83	0.28	0.91	0.44	0.93	0.98	-0.8	0.93	0.92	0.95	0.99	0.87	0.91
Total Stockholder Equity	0.84	0.35	0.13	0.56		0.82	-0.83	0.65	0.69	0.1	0.82	0.71	0.87	0.65	0.77	0.75	0.7	0.6	0.68	-0.62	0.77	0.78	0.32	0.57	0.83	0.77
Other Liab	0.78	0.47	0.21	0.67	0.82		-0.76	0.63	0.72	-0.06	0.67	0.48	0.82	0.7	0.57	0.74	0.47	0.58	0.69	-0.59	0.74	0.75	0.46	0.72	0.84	0.67
Net Tangible Assets	-0.95	-0.63	-0.43	-0.87	-0.83	-0.76		-0.93	-0.96	0.47	-0.72	-0.68	-0.99	-0.92	-0.5	-0.97	-0.66	-0.91	-0.93	0.9	-0.98	-0.98	-0.73	-0.86	-0.91	-0.98
Property Plant And Equipment Net	0.85	0.7	0.49	0.88	0.65	0.63	-0.93		0.97	-0.62	0.56	0.6	0.92	0.93	0.43	0.98	0.59	0.96	0.92	-0.97	0.96	0.97	0.85	0.89	0.87	0.94
Net Debt	0.9	0.7	0.51	0.93	0.69	0.72	-0.96	0.97		-0.62	0.59	0.58	0.95	0.97	0.41	0.99	0.56	0.95	0.95	-0.95	0.97	0.98	0.85	0.93	0.9	0.96
Retained Earnings	-0.35	-0.57	-0.53	-0.66	0.1	-0.06	0.47	-0.62	-0.62		-0.02	-0.02	-0.39	-0.61	0.33	-0.55	-0.01	-0.67	-0.58	0.62	-0.52	-0.51	-0.8	-0.63	-0.34	-0.53
Accounts Payable	0.66	0.25	-0.26	0.39	0.82	0.67	-0.72	0.56	0.59	-0.02		0.45	0.73	0.6	0.43	0.63	0.44	0.44	0.48	-0.58	0.63	0.63	0.21	0.39	0.59	0.63
Cash	0.67	0.31	0.25	0.45	0.71	0.48	-0.68	0.6	0.58	-0.02	0.45		0.67	0.56	0.68	0.64	1.0	0.52	0.55	-0.6	0.63	0.66	0.29	0.46	0.56	0.63
Non Current Assets Total	0.96	0.63	0.43	0.87	0.87	0.82	-0.99	0.92	0.95	-0.39	0.73	0.67		0.89	0.56	0.97	0.65	0.89	0.93	-0.87	0.98	0.98	0.73	0.88	0.95	0.97
Non Currrent Assets Other	0.83	0.62	0.36	0.83	0.65	0.7	-0.92	0.93	0.97	-0.61	0.6	0.56	0.89		0.4	0.94	0.55	0.87	0.85	-0.96	0.9	0.92	0.75	0.83	0.84	0.89
Other Assets	0.55	0.17	0.11	0.28	0.77	0.57	-0.5	0.43	0.41	0.33	0.43	0.68	0.56	0.4		0.47	0.68	0.31	0.41	-0.42	0.47	0.49	0.1	0.32	0.64	0.44
Long Term Debt	0.92	0.69	0.5	0.91	0.75	0.74	-0.97	0.98	0.99	-0.55	0.63	0.64	0.97	0.94	0.47		0.62	0.95	0.95	-0.95	0.99	1.0	0.82	0.91	0.92	0.97
Cash And Short Term Investments	0.66	0.3	0.25	0.44	0.7	0.47	-0.66	0.59	0.56	-0.01	0.44	1.0	0.65	0.55	0.68	0.62		0.5	0.53	-0.59	0.61	0.64	0.27	0.44	0.54	0.61
Net Receivables	0.85	0.72	0.67	0.93	0.6	0.58	-0.91	0.96	0.95	-0.67	0.44	0.52	0.89	0.87	0.31	0.95	0.5		0.96	-0.89	0.95	0.95	0.91	0.93	0.86	0.95
Good Will	0.93	0.73	0.7	0.98	0.68	0.69	-0.93	0.92	0.95	-0.58	0.48	0.55	0.93	0.85	0.41	0.95	0.53	0.96		-0.83	0.97	0.96	0.9	0.97	0.93	0.96
Short Term Investments	-0.79	-0.63	-0.35	-0.8	-0.62	-0.59	0.9	-0.97	-0.95	0.62	-0.58	-0.6	-0.87	-0.96	-0.42	-0.95	-0.59	-0.89	-0.83		-0.9	-0.92	-0.75	-0.79	-0.8	-0.89
Long Term Debt Total	0.94	0.7	0.54	0.93	0.77	0.74	-0.98	0.96	0.97	-0.52	0.63	0.63	0.98	0.9	0.47	0.99	0.61	0.95	0.97	-0.9		1.0	0.83	0.93	0.93	0.98
Non Current Liabilities Total	0.94	0.68	0.52	0.92	0.78	0.75	-0.98	0.97	0.98	-0.51	0.63	0.66	0.98	0.92	0.49	1.0	0.64	0.95	0.96	-0.92	1.0		0.82	0.92	0.93	0.98
Capital Surpluse	0.71	0.76	0.77	0.95	0.32	0.46	-0.73	0.85	0.85	-0.8	0.21	0.29	0.73	0.75	0.1	0.82	0.27	0.91	0.9	-0.75	0.83	0.82		0.94	0.74	0.8
Inventory	0.86	0.76	0.72	0.99	0.57	0.72	-0.86	0.89	0.93	-0.63	0.39	0.46	0.88	0.83	0.32	0.91	0.44	0.93	0.97	-0.79	0.93	0.92	0.94		0.89	0.89
Other Current Assets	0.93	0.63	0.53	0.87	0.83	0.84	-0.91	0.87	0.9	-0.34	0.59	0.56	0.95	0.84	0.64	0.92	0.54	0.86	0.93	-0.8	0.93	0.93	0.74	0.89		0.9
Other Stockholder Equity	0.94	0.65	0.54	0.91	0.77	0.67	-0.98	0.94	0.96	-0.53	0.63	0.63	0.97	0.89	0.44	0.97	0.61	0.95	0.96	-0.89	0.98	0.98	0.8	0.89	0.9

Click cells to compare fundamentals

Amneal Pharmaceuticals, Account Relationship Matchups

Amneal Pharmaceuticals, fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	4.0B	3.9B	3.8B	3.5B	4.0B	3.2B
Common Stock Shares Outstanding	148.9M	151.8M	150.9M	176.1M	202.6M	151.5M
Other Current Liab	459.8M	495.8M	481.0M	475.4M	546.7M	275.3M
Total Current Liabilities	676.9M	677.2M	752.8M	846.6M	973.6M	589.0M
Total Stockholder Equity	344.9M	367.0M	184.0M	19.8M	22.7M	21.6M
Other Liab	35.7M	87.3M	48.5M	97.1M	111.7M	75.0M
Net Tangible Assets	(1.6B)	(1.5B)	(1.4B)	(1.4B)	(1.2B)	(1.3B)
Property Plant And Equipment Net	595.2M	639.0M	589.4M	550.1M	632.7M	579.3M
Net Debt	2.6B	2.6B	2.8B	2.7B	3.1B	2.1B
Retained Earnings	(286.8M)	(276.2M)	(406.2M)	(490.2M)	(441.2M)	(463.2M)
Accounts Payable	154.1M	132.9M	166.8M	143.6M	165.1M	222.4M
Cash	341.4M	247.8M	26.0M	91.5M	105.3M	150.8M
Non Current Assets Total	2.5B	2.4B	2.4B	2.1B	2.4B	2.0B
Non Currrent Assets Other	31.9M	20.6M	103.2M	18.4M	21.2M	22.3M
Other Assets	16.5M	149.3M	473.7M	17.6M	20.3M	19.3M
Long Term Debt	2.7B	2.7B	2.6B	2.4B	2.8B	2.2B
Cash And Short Term Investments	341.4M	247.8M	26.0M	91.5M	105.3M	152.0M
Net Receivables	674.2M	662.6M	741.8M	613.7M	705.8M	590.6M
Good Will	522.8M	593.0M	598.9M	598.6M	688.4M	396.5M
Short Term Investments	1.7M	1.2M	1.8M	2.2M	2.0M	1.9M
Long Term Debt Total	2.7B	2.7B	2.7B	2.6B	3.0B	2.1B
Non Current Liabilities Total	3.0B	2.9B	2.8B	2.6B	3.0B	2.5B
Capital Surpluse	607.0M	628.4M	658.4M	691.6M	795.4M	648.3M
Inventory	490.6M	489.4M	530.7M	581.4M	668.6M	454.1M
Other Current Assets	80.5M	120.3M	113.3M	91.2M	104.9M	85.3M
Other Stockholder Equity	670.1M	658.4M	691.6M	539.2M	620.1M	463.4M
Total Liab	3.7B	3.6B	3.6B	3.5B	4.0B	3.1B
Short Long Term Debt	45.2M	30.6M	90.0M	213.1M	245.1M	257.3M
Total Current Assets	1.6B	1.5B	1.4B	1.4B	1.6B	1.3B
Short Term Debt	57.5M	46.0M	104.6M	227.6M	261.8M	274.9M
Intangible Assets	1.3B	1.2B	1.1B	890.4M	1.0B	933.3M
Common Stock	3.0M	3.0M	3.0M	3.1M	3.5M	3.2M
Property Plant Equipment	620.6M	477.8M	514.2M	469.8M	540.3M	513.5M
Short Long Term Debt Total	2.9B	2.9B	2.8B	2.8B	3.2B	2.9B
Noncontrolling Interest In Consolidated Entity	114.8M	41.7M	6.6M	(114.4M)	(103.0M)	(97.8M)
Common Stock Total Equity	3.0M	3.0M	3.0M	3.0M	3.5M	2.8M
Retained Earnings Total Equity	(377.9M)	(286.8M)	(276.2M)	(406.2M)	(365.6M)	(347.3M)
Liabilities And Stockholders Equity	4.0B	3.9B	3.8B	3.5B	4.0B	3.9B
Capital Lease Obligations	123.9M	127.4M	123.5M	109.9M	126.4M	110.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

EBR	Centrais Electricas Brasileiras
HE	Hawaiian Electric Industries
VFC	VF Corporation

Additional Tools for Amneal Stock Analysis

When running Amneal Pharmaceuticals,'s price analysis, check to measure Amneal Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals, is operating at the current time. Most of Amneal Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Amneal Gross Profit Margin vs Asset Turnover Analysis

Gross Profit Margin vs Asset Turnover

Gross Profit Margin vs Asset Turnover Correlation Analysis

Correlation Coefficient

Gross Profit Margin

Asset Turnover

Amneal Pharmaceuticals, fundamental ratios Correlations

Amneal Pharmaceuticals, Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Amneal Pharmaceuticals, fundamental ratios Accounts

Also Currently Popular

Additional Tools for Amneal Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Non Current Liabilities Total	+ 1.0	Long Term Debt
Non Current Liabilities Total	+ 1.0	Long Term Debt Total
Inventory	+ 0.99	Total Current Liabilities
Long Term Debt	+ 0.99	Net Debt
Long Term Debt Total	+ 0.99	Long Term Debt

Non Current Assets Total	- 0.99	Net Tangible Assets
Other Stockholder Equity	- 0.98	Net Tangible Assets
Non Current Liabilities Total	- 0.98	Net Tangible Assets
Long Term Debt Total	- 0.98	Net Tangible Assets
Short Term Investments	- 0.97	Property Plant And Equipment Net
Long Term Debt	- 0.97	Net Tangible Assets